News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regado Biosciences, Inc. (RGDO) Kicks Off Big Clinical Trial for Heart Drug


9/17/2013 8:07:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Regado Biosciences (NASDAQ: RGDO) will now have the chance to prove that the two-pronged anticoagulant it pitched at its IPO roadshow is all it’s cracked up to be. The Basking Ridge, NJ-based biotech has officially enrolled the first patient in a massive late-stage clinical trial for its lead drug, REG-1. Regado expects to enroll a total of 13,200 patients at 500 sites around the world and complete the trial in 2015.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy

comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES